The Novel Therapeutics Delivery program aims to foster the development of novel technologies and techniques for the delivery of existing or innovative therapies by working at the intersection of engineering, biology, chemistry, and medicine. Specifically, it strives to capitalize and incentivize translational projects to address complex challenges in “therapeutic” delivery – from biomanufacturing, to targeted delivery, to biomaterials and more.
Up to $5 million capital dollars are available for the current program round, with each award anticipated to be up to $750,000 to support work and equipment at not-for-profit partners.
The application period will run from July 31 to Nov. 17, 2023 at 5 p.m. EST.
Eligibility & Evaluation
Eligibility criteria include multiple factors, such as applicants must be a Massachusetts legally organized “not-for-profit” entity such as an academic/research institution, a hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.
To evaluate an external panel of scientists from academia and industry with expertise in delivery/development of therapeutics and clinical care will review them based on the following criteria:
- Qualifications of the Team
- Use of funds and value to the MA ecosystem
- Proposed plan, unmet need/market opportunity, data generation and sharing (if applicable), scientist training, and approach to solving a key question.
Top applicants will be asked to present their proposed project plan to our review panel.
Please view the full list of eligibility requirements and evaluation process.
Impact on the Ecosystem
Innovative new therapies are dependent on advancements in drug delivery. Increased drug complexity, the rise of biopharmaceuticals, novel therapeutic technologies, bioavailability challenges, and the demand for the demonstration of strong drug performance are all driving unprecedented technology innovation; however, the availability of such therapies is not accelerating at the rate with which technology is advancing. Existing therapies can also benefit from improved delivery methods and devices, increasing patient compliance and improving overall health.
Connect with Us to Learn More
If you have any questions regarding the application process, e-mail: DrugDelivery@Masslifesciences.com.